Moreover, the study also analyzed differentially expressed ci-miRNAs in HER2-positive and HER2-negative breast cancer patients; elevated ci-miRNA-375 and reduced ci-miRNA-122 levels correlate with positive HER2 status, response to neoadjuvant chemotherapy and absence of relapse [112]. The gene discussed is ERBB2; the disease is breast cancer.